PE20100570A1 - Antagonistas de cgrp seleccionados y procedimientos para su preparacion - Google Patents
Antagonistas de cgrp seleccionados y procedimientos para su preparacionInfo
- Publication number
- PE20100570A1 PE20100570A1 PE2010000353A PE2010000353A PE20100570A1 PE 20100570 A1 PE20100570 A1 PE 20100570A1 PE 2010000353 A PE2010000353 A PE 2010000353A PE 2010000353 A PE2010000353 A PE 2010000353A PE 20100570 A1 PE20100570 A1 PE 20100570A1
- Authority
- PE
- Peru
- Prior art keywords
- oxo
- piperidin
- amino
- benzdiazepin
- carboximethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA TALES COMO: ESTER (R)-1-(4-AMINO-3-CLORO-5-TRIFLUOROMETIL-BENCIL)-2-[4-(CARBOXIMETIL-AMINO)-1,4'-BIPIPERIDINIL-1'-IL]-2-OXO-ETILICO DEL ACIDO 4-(2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENZDIAZEPIN-3-IL)-PIPERIDIN-1-CARBOXILICO, ESTER (R)-1-(4-AMINO-3-CLORO-5-TRIFLUOROMETIL-BENCIL)-2-(1'-CARBOXIMETIL-4,4'-BIPIPERIDINIL-1-IL)-2-OXO-ETILICO DEL ACIDO 4-(2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENZDIAZEPIN-3-IL)-PIPERIDIN-1-CARBOXILICO, ESTER (R)-1-(4-AMINO-3-CLORO-5-TRIFLUOROMETIL-BENCIL)-2-[4-(4-CARBOXIMETIL-PIPERAZIN-1-IL)-PIPERIDIN-1-IL]-2-OXO-ETILICO DEL ACIDO 4-(2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENZDIAZEPIN-3-IL)-PIPERIDIN-1-CARBOXILICO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL PEPTIDO DERIVADO DEL GEN DE LA CALCITONINA (CGRP) SIENDO UTILES EN EL TRATAMIENTO DE MIGRANA, DIABETES MELLITUS, ARTRITIS REUMATOIDE, ASMA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005038831A DE102005038831A1 (de) | 2005-08-17 | 2005-08-17 | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102005050953A DE102005050953A1 (de) | 2005-08-17 | 2005-10-25 | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20100570A1 true PE20100570A1 (es) | 2010-08-16 |
Family
ID=37496772
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000989A PE20070355A1 (es) | 2005-08-17 | 2006-08-15 | Antagonistas de cgrp seleccionados y procedimientos para su preparacion |
PE2010000353A PE20100570A1 (es) | 2005-08-17 | 2006-08-15 | Antagonistas de cgrp seleccionados y procedimientos para su preparacion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000989A PE20070355A1 (es) | 2005-08-17 | 2006-08-15 | Antagonistas de cgrp seleccionados y procedimientos para su preparacion |
Country Status (18)
Country | Link |
---|---|
US (3) | US7579341B2 (es) |
EP (1) | EP1917256A2 (es) |
JP (2) | JP4852607B2 (es) |
KR (1) | KR20080039990A (es) |
AR (1) | AR056460A1 (es) |
AU (1) | AU2006281416A1 (es) |
BR (1) | BRPI0614831A2 (es) |
CA (1) | CA2618834A1 (es) |
DE (2) | DE102005038831A1 (es) |
EA (1) | EA200800439A1 (es) |
EC (1) | ECSP088194A (es) |
IL (1) | IL189497A0 (es) |
MX (1) | MX2008001977A (es) |
NO (1) | NO20076680L (es) |
PE (2) | PE20070355A1 (es) |
TW (1) | TW200740795A (es) |
UY (1) | UY29749A1 (es) |
WO (1) | WO2007020261A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595312B2 (en) * | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
DE10250082A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7491717B2 (en) * | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (de) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
EP1770086A1 (de) * | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
AU2007255395A1 (en) * | 2006-06-08 | 2007-12-13 | Boehringer Ingelheim International Gmbh | Treatment of gastrointestinal disorders with CGRP-antagonists |
DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
JP2010540494A (ja) | 2007-09-28 | 2010-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
USD922701S1 (en) | 2019-12-23 | 2021-06-15 | Samsung Electronics Co., Ltd. | Shoe care machine |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ82399A3 (cs) | 1996-09-10 | 1999-06-16 | Dr. Karl Thomae Gmbh | Modifikované aminokyseliny, způsob jejich výroby a farmaceutický prostředek s jejich obsahem |
US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
DE10250080A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE10300973A1 (de) | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US20050282857A1 (en) | 2004-04-15 | 2005-12-22 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102004018796A1 (de) * | 2004-04-15 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004018795A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004019492A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004044145B3 (de) * | 2004-09-13 | 2006-04-13 | Robert Bosch Gmbh | Reflektormodul für einen photometrischen Gassensor |
DE102004063752A1 (de) | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
DE102004063753A1 (de) | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7491717B2 (en) | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
US7439237B2 (en) | 2005-04-15 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
DE102005038831A1 (de) * | 2005-08-17 | 2007-02-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
EP1770086A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
-
2005
- 2005-08-17 DE DE102005038831A patent/DE102005038831A1/de not_active Withdrawn
- 2005-10-25 DE DE102005050953A patent/DE102005050953A1/de not_active Withdrawn
-
2006
- 2006-08-04 US US11/462,511 patent/US7579341B2/en active Active
- 2006-08-14 UY UY29749A patent/UY29749A1/es not_active Application Discontinuation
- 2006-08-15 JP JP2008526494A patent/JP4852607B2/ja not_active Expired - Fee Related
- 2006-08-15 BR BRPI0614831-0A patent/BRPI0614831A2/pt not_active IP Right Cessation
- 2006-08-15 PE PE2006000989A patent/PE20070355A1/es not_active Application Discontinuation
- 2006-08-15 PE PE2010000353A patent/PE20100570A1/es not_active Application Discontinuation
- 2006-08-15 CA CA002618834A patent/CA2618834A1/en not_active Abandoned
- 2006-08-15 WO PCT/EP2006/065314 patent/WO2007020261A2/de active Application Filing
- 2006-08-15 AU AU2006281416A patent/AU2006281416A1/en not_active Abandoned
- 2006-08-15 EA EA200800439A patent/EA200800439A1/ru unknown
- 2006-08-15 KR KR1020087006215A patent/KR20080039990A/ko not_active Application Discontinuation
- 2006-08-15 EP EP06778243A patent/EP1917256A2/de not_active Withdrawn
- 2006-08-15 MX MX2008001977A patent/MX2008001977A/es not_active Application Discontinuation
- 2006-08-16 AR ARP060103563A patent/AR056460A1/es unknown
- 2006-08-16 TW TW095130108A patent/TW200740795A/zh unknown
-
2007
- 2007-12-28 NO NO20076680A patent/NO20076680L/no not_active Application Discontinuation
-
2008
- 2008-02-13 IL IL189497A patent/IL189497A0/en unknown
- 2008-02-15 EC EC2008008194A patent/ECSP088194A/es unknown
-
2009
- 2009-06-17 US US12/486,026 patent/US7858622B2/en active Active
-
2010
- 2010-10-19 US US12/907,771 patent/US20110034444A1/en not_active Abandoned
-
2011
- 2011-08-31 JP JP2011189050A patent/JP2011256200A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
PE20070355A1 (es) | 2007-04-30 |
EP1917256A2 (de) | 2008-05-07 |
US20070049581A1 (en) | 2007-03-01 |
DE102005038831A1 (de) | 2007-02-22 |
EA200800439A1 (ru) | 2008-08-29 |
UY29749A1 (es) | 2007-03-30 |
KR20080039990A (ko) | 2008-05-07 |
JP2009505985A (ja) | 2009-02-12 |
JP4852607B2 (ja) | 2012-01-11 |
TW200740795A (en) | 2007-11-01 |
DE102005050953A1 (de) | 2007-04-26 |
AR056460A1 (es) | 2007-10-10 |
US20110034444A1 (en) | 2011-02-10 |
US20100004228A1 (en) | 2010-01-07 |
BRPI0614831A2 (pt) | 2009-05-19 |
US7579341B2 (en) | 2009-08-25 |
AU2006281416A1 (en) | 2007-02-22 |
WO2007020261A3 (de) | 2008-08-21 |
CA2618834A1 (en) | 2007-02-22 |
NO20076680L (no) | 2008-04-30 |
ECSP088194A (es) | 2008-03-26 |
MX2008001977A (es) | 2008-03-25 |
WO2007020261A2 (de) | 2007-02-22 |
IL189497A0 (en) | 2008-08-07 |
JP2011256200A (ja) | 2011-12-22 |
US7858622B2 (en) | 2010-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20100570A1 (es) | Antagonistas de cgrp seleccionados y procedimientos para su preparacion | |
PE20130340A1 (es) | (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida como antagonista del receptor de peptido relacionado con el gen de la calcitonina (cgrp) | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
WO2006102308A3 (en) | Beta-lactamyl vasopressin v1b antagonists | |
CL2007003755A1 (es) | Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe | |
CL2007001662A1 (es) | Uso de compuestos especificos derivados de 2-oxo-1,2,4,5-tetrahidro-1,3-benzodiazepin-3-ilpiperidina antagonistas de cgrp para preparar un medicamento util para prevenir o tratar el dolor visceral y para prevenir o tratar trastornos gastrointestinales; composicion farmaceutica; y uso de la composicion. | |
CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
CL2007003440A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida | |
PE20060176A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos | |
CL2007002288A1 (es) | Compuestos derivados de imidazol-amina condensados, inhibidores de la beta-secretasa; proceso de preparacion; composicion farmaceutica, util para el tratamiento, prevencion o mejoramiento de enfermedades tales como enfermedad de alzheimer, deterioro | |
CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
JP2008513516A5 (es) | ||
MX2009004467A (es) | Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk). | |
CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
TW200734343A (en) | Indol-3-yl-carbonyl-spiro-piperidine derivatives | |
TW200716107A (en) | Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | |
BRPI0906104A2 (pt) | "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto" | |
MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
TW200726469A (en) | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | |
WO2007011878A3 (en) | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists | |
PE20070619A1 (es) | TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA | |
CL2007002689A1 (es) | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. | |
JO2937B1 (en) | Tight muscles of the peptide vascular tensioner receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |